• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated

• Phase 2 proof-of-concept study in patients with ADPKD remains on-track to initiate in the fourth quarter of 2026

• SCY-770 is a potential first-in-class oral direct AMPK activator designed to address multiple underlying drivers of cyst growth and disease progression in ADPKD

JERSEY CITY, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced completion of a Phase 1 study of SCY-770, a first-in-class, selective and direct AMP-activated protein kinase (AMPK) activator. The study was conducted to evaluate the safety and tolerability, as well as to characterize the pharmacokinetics of SCY-770 to support dose selection for the Phase 2 study in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.